Article Text

Download PDFPDF
Risk of COVID-19 and smoking
  1. Ivan Berlin1,2
  1. 1 Department of Pharmacology, Hôpital Pitié-Salpêtrière-Sorbonne Université, Paris, France
  2. 2 Centre Universitaire de Médecine Générale et Santé Publique, UNISANTE, Université de Lausanne Faculté de Biologie et Médecine, Lausanne, Switzerland
  1. Correspondence to Dr Ivan Berlin, Department of pharmacology, Hôpital Pitié-Salpêtrière-Sorbonne Université, Paris 75013, France;{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To the Editor

According to several reports, peer-reviewed or in preprint servers, smokers are under-represented among individuals tested positive (reverse transcription (RT)-PCR) for SARS-CoV-2 and diagnosed with COVID-19. Hippisley-Cox et al 1 also report a markedly reduced prevalence of light, moderate and heavy smokers among those tested positive for SARS-CoV-2 or admitted to an intensive care unit, findings similar to those reported by de Lusignan et al.2 The association does not seem to be dose-dependent/exposure-dependent,1 unlike the usually dose-dependent/exposure-dependent smoking–health disorder associations. These findings led to the hypothesis that, …

View Full Text


  • Contributors IB is the sole author of this letter.

  • Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles